NASDAQ · APVO
Healthcare · Biotechnology
$1.36
Up+$0.01 (+0.74%)
Updated Nov 4, 2026, 4:09 AM
SID Score
3.6/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · APVO
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 3, 2026
APVO closed at $1.36 after 21 trading sessions, down 24.23% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 3, 2026 | $1.44 | $1.44 | $1.31 | $1.36 | 13.98K |
| Nov 2, 2026 | $1.3925 | $1.3976 | $1.3294 | $1.35 | 23.05K |
| Oct 30, 2026 | $1.36 | $1.3864 | $1.31 | $1.34 | 28.69K |
| Oct 29, 2026 | $1.32 | $1.41 | $1.31 | $1.36 | 58.51K |
| Oct 28, 2026 | $1.36 | $1.3699 | $1.26 | $1.30 | 42.35K |
| Oct 27, 2026 | $1.55 | $1.58 | $1.2525 | $1.28 | 80.7K |
| Oct 26, 2026 | $1.74 | $1.74 | $1.43 | $1.50 | 123.73K |
| Oct 23, 2026 | $1.61 | $1.6362 | $1.60 | $1.61 | 7.18K |
| Oct 22, 2026 | $1.605 | $1.64 | $1.60 | $1.61 | 5.29K |
| Oct 21, 2026 | $1.63 | $1.65 | $1.60 | $1.60 | 8.69K |
| Oct 20, 2026 | $1.6004 | $1.65 | $1.60 | $1.615 | 12.57K |
| Oct 19, 2026 | $1.655 | $1.655 | $1.5682 | $1.60 | 8.43K |
| Oct 16, 2026 | $1.73 | $1.73 | $1.60 | $1.62 | 31.62K |
| Oct 15, 2026 | $1.73 | $1.74 | $1.70 | $1.70 | 11.31K |
| Oct 14, 2026 | $1.73 | $1.78 | $1.71 | $1.73 | 22.25K |
| Oct 13, 2026 | $1.79 | $1.79 | $1.70 | $1.73 | 85.93K |
| Oct 12, 2026 | $1.79 | $1.97 | $1.76 | $1.8363 | 286.36K |
| Oct 9, 2026 | $1.79 | $1.81 | $1.78 | $1.79 | 6.82K |
| Oct 8, 2026 | $1.77 | $1.84 | $1.77 | $1.80 | 26.9K |
| Oct 7, 2026 | $1.76 | $1.85 | $1.76 | $1.84 | 12.15K |
| Oct 6, 2026 | $1.82 | $1.92 | $1.79 | $1.795 | 35.4K |
The latest Smart Investors Daily articles mentioning APVO.
Company
Market Activity
Research & News
APVO research
Company profile and research snapshot.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 23, 2024 | Roth MKM | Buy | — |
| May 13, 2022 | Piper Sandler | Overweight | — |
| May 28, 2021 | Roth Capital | Buy | — |
| Nov 11, 2020 | Piper Sandler | Overweight | — |
| Apr 11, 2018 | Roth Capital | Buy | — |
No generated briefing is available yet.
Yahoo · Aug 14, 2026
Mipletamig Drives Clinical Momentum with Strong Frontline AML Data, Path Toward Phase 2 Chief Scientific Officer Appointment Strengthens Execution Across Advancing Oncology Pipeline Non-Dilutive Grant Funding Advances APVO451 and Validates Trispecific ...
Benzinga · Aug 14, 2026
Aptevo Therapeutics (NASDAQ:APVO) reported quarterly losses of $(5.31) per share which beat the analyst consensus estimate of $(6.16) by 13.8 percent. This is a 96.49 percent increase over losses of $(151.20) per share
Benzinga · Feb 3, 2026
Aptevo Therapeutics Inc. (Nasdaq:APVO), a clinical-stage biotechnology company developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, today
accessnewswire.com · Dec 9, 2025
100% of patients in Cohorts 1-3 remain free of cytokine release syndrome CRIS-7-derived CD3 design underpins a controlled T-cell response, supporting the differentiated safety profile, combinability with standard of care SEATTLE, WA / ACCESS Newswire / December 9, 2025 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, presented preliminary results from its ongoing Phase 1b/2 RAINIER study evaluating mipletamig, a CD123 x CD3 bispecific molecule, in combination with azacitidine and venetoclax (AZA/VEN) for newly diagnosed acute myeloid leukemia (AML) patients who are unfit for intensive chemotherapy. The data were presented on December 8, 2025, in a poster session at the American Society of Hematology (ASH) Annual Meeting.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning APVO.
